Karyopharm Therapeutics Inc. Research and Development Expense
Karyopharm Therapeutics Inc. (KPTI) reported Research and Development Expense of $28.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Karyopharm Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $28.96M, a 11.68% decline year-over-year.
- Karyopharm Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $33.80M, a 2.37% decline year-over-year.
- Karyopharm Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $27.67M, a 16.92% decline year-over-year.
- Karyopharm Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $30.54M, a 15.47% decline year-over-year.
- Karyopharm Therapeutics Inc. research and development expense for fiscal 2025 was $125.62M, a 12.30% decline from fiscal 2024.
- Karyopharm Therapeutics Inc. research and development expense for fiscal 2024 was $143.23M, a 3.23% increase from fiscal 2023.
- Karyopharm Therapeutics Inc. research and development expense for fiscal 2023 was $138.75M, a 6.67% decline from fiscal 2022.
- Karyopharm Therapeutics Inc. research and development expense for fiscal 2022 was $148.66M, a 7.57% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 57 month | Research and Development Expense 60 month | Research and Development Expense 63 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.96M 10-Q · filed 2026-08-13 | $62.75M 10-Q · filed 2026-08-13 | $90.42M derived: sum of 3 quarters · filed 2026-08-13 | $120.97M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $33.80M 10-Q · filed 2026-05-14 | $61.46M derived: sum of 2 quarters · filed 2026-05-14 | $92.01M derived: sum of 3 quarters · filed 2026-05-14 | $124.80M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $27.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $58.21M derived: sum of 2 quarters · filed 2026-02-13 | $91.00M derived: sum of 3 quarters · filed 2026-08-13 | $125.62M 10-K · filed 2026-02-13 | |||
| 2025-09-30 | $30.54M 10-Q · filed 2025-11-03 | $63.33M derived: sum of 2 quarters · filed 2026-08-13 | $97.95M 10-Q · filed 2025-11-03 | $131.25M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $32.79M 10-Q · filed 2026-08-13 | $67.41M 10-Q · filed 2026-08-13 | $100.71M derived: sum of 3 quarters · filed 2026-08-13 | $136.84M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $34.62M 10-Q · filed 2026-05-14 | $67.92M derived: sum of 2 quarters · filed 2026-05-14 | $104.05M derived: sum of 3 quarters · filed 2026-05-14 | $142.43M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $33.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $69.44M derived: sum of 2 quarters · filed 2026-02-13 | $107.81M derived: sum of 3 quarters · filed 2026-02-13 | $143.23M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $36.13M 10-Q · filed 2025-11-03 | $74.50M derived: sum of 2 quarters · filed 2025-11-03 | $109.93M 10-Q · filed 2025-11-03 | $149.31M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-06-30 | $38.37M 10-Q · filed 2025-08-11 | $73.80M 10-Q · filed 2025-08-11 | $113.18M derived: sum of 3 quarters · filed 2026-02-13 | $148.73M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-03-31 | $35.42M 10-Q · filed 2025-05-12 | $74.81M derived: sum of 2 quarters · filed 2026-02-13 | $110.36M derived: sum of 3 quarters · filed 2026-02-13 | $141.84M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2023-12-31 | $39.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $74.93M derived: sum of 2 quarters · filed 2026-02-13 | $106.41M derived: sum of 3 quarters · filed 2026-02-13 | $138.75M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $35.55M 10-Q · filed 2024-11-05 | $67.03M derived: sum of 2 quarters · filed 2024-11-05 | $99.37M 10-Q · filed 2024-11-05 | $130.30M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $31.48M 10-Q · filed 2024-08-06 | $63.82M 10-Q · filed 2024-08-06 | $94.75M derived: sum of 3 quarters · filed 2025-02-19 | $126.11M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | $32.34M 10-Q · filed 2024-05-08 | $63.27M derived: sum of 2 quarters · filed 2025-02-19 | $94.63M derived: sum of 3 quarters · filed 2025-02-19 | $138.94M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | $30.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $62.29M derived: sum of 2 quarters · filed 2025-02-19 | $106.60M derived: sum of 3 quarters · filed 2025-02-19 | $148.66M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $31.36M 10-Q · filed 2023-11-02 | $75.67M derived: sum of 2 quarters · filed 2023-11-02 | $117.73M 10-Q · filed 2023-11-02 | $161.73M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-06-30 | $44.31M 10-Q · filed 2023-08-02 | $86.37M 10-Q · filed 2023-08-02 | $130.37M derived: sum of 3 quarters · filed 2024-02-29 | $176.18M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | $42.06M 10-Q · filed 2023-05-04 | $86.06M derived: sum of 2 quarters · filed 2024-02-29 | $131.87M derived: sum of 3 quarters · filed 2024-02-29 | $165.85M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | $44.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $89.81M derived: sum of 2 quarters · filed 2024-02-29 | $123.79M derived: sum of 3 quarters · filed 2024-02-29 | $160.84M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $45.81M 10-Q · filed 2022-11-03 | $79.79M derived: sum of 2 quarters · filed 2022-11-03 | $116.84M 10-Q · filed 2022-11-03 | $154.02M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-06-30 | $33.98M 10-Q · filed 2022-08-04 | $71.03M 10-Q · filed 2022-08-04 | $108.22M derived: sum of 3 quarters · filed 2023-02-17 | $145.25M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-03-31 | $37.05M 10-Q · filed 2022-05-05 | $74.23M derived: sum of 2 quarters · filed 2023-02-17 | $111.27M derived: sum of 3 quarters · filed 2023-02-17 | $153.87M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2020-12-31 | $37.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $74.22M derived: sum of 2 quarters · filed 2023-02-17 | $116.82M derived: sum of 3 quarters · filed 2023-02-17 | $150.81M 10-K · filed 2023-02-17 | |||
| 2020-09-30 | $37.04M 10-Q · filed 2021-11-03 | $79.63M derived: sum of 2 quarters · filed 2021-11-03 | $113.63M 10-Q · filed 2021-11-03 | $145.21M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $42.59M 10-Q · filed 2021-08-05 | $76.59M 10-Q · filed 2021-08-05 | $108.17M derived: sum of 3 quarters · filed 2022-03-01 | $134.44M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $34.00M 10-Q · filed 2021-05-04 | $65.58M derived: sum of 2 quarters · filed 2022-03-01 | $91.85M derived: sum of 3 quarters · filed 2022-03-01 | $118.36M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $31.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $57.85M derived: sum of 2 quarters · filed 2022-03-01 | $84.37M derived: sum of 3 quarters · filed 2022-03-01 | $122.34M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $26.27M 10-Q · filed 2020-11-02 | $52.79M derived: sum of 2 quarters · filed 2020-11-02 | $90.76M 10-Q · filed 2020-11-02 | $129.65M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-06-30 | $26.52M 10-Q · filed 2020-08-04 | $64.49M 10-Q · filed 2020-08-04 | $103.38M derived: sum of 3 quarters · filed 2021-02-24 | $139.81M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-03-31 | $37.97M 10-Q · filed 2020-05-05 | $76.86M derived: sum of 2 quarters · filed 2021-02-24 | $113.29M derived: sum of 3 quarters · filed 2021-02-24 | $158.03M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2018-12-31 | $38.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $75.32M derived: sum of 2 quarters · filed 2021-02-24 | $120.05M derived: sum of 3 quarters · filed 2021-02-24 | $161.37M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $36.43M 10-Q · filed 2019-11-04 | $81.16M derived: sum of 2 quarters · filed 2019-11-04 | $122.48M 10-Q · filed 2019-11-04 | $157.31M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-06-30 | $44.73M 10-Q · filed 2019-08-07 | $86.06M 10-Q · filed 2019-08-07 | $120.89M derived: sum of 3 quarters · filed 2020-02-26 | $146.13M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-03-31 | $41.32M 10-Q · filed 2019-05-09 | $76.15M derived: sum of 2 quarters · filed 2020-02-26 | $101.39M derived: sum of 3 quarters · filed 2020-02-26 | $124.51M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2017-12-31 | $34.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $60.07M derived: sum of 2 quarters · filed 2020-02-26 | $83.19M derived: sum of 3 quarters · filed 2020-02-26 | $107.27M 10-K · filed 2020-02-26 | |||
| 2017-09-30 | $25.24M 10-Q · filed 2018-11-08 | $48.36M derived: sum of 2 quarters · filed 2018-11-08 | $72.44M 10-Q · filed 2018-11-08 | $93.11M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-06-30 | $23.12M 10-Q · filed 2018-08-07 | $47.20M 10-Q · filed 2018-08-07 | $67.87M derived: sum of 3 quarters · filed 2019-02-28 | $87.77M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-03-31 | $24.08M 10-Q · filed 2018-05-10 | $44.75M derived: sum of 2 quarters · filed 2019-02-28 | $64.65M derived: sum of 3 quarters · filed 2019-02-28 | $89.23M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2016-12-31 | $20.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $40.56M derived: sum of 2 quarters · filed 2019-02-28 | $65.14M derived: sum of 3 quarters · filed 2019-02-28 | $86.94M 10-K · filed 2019-02-28 | |||
| 2016-09-30 | $19.89M 10-Q · filed 2017-11-02 | $44.47M derived: sum of 2 quarters · filed 2017-11-02 | $66.27M 10-Q · filed 2017-11-02 | $90.33M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2016-06-30 | $24.58M 10-Q · filed 2017-08-08 | $46.37M 10-Q · filed 2017-08-08 | $70.44M derived: sum of 3 quarters · filed 2018-03-15 | $96.36M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2016-03-31 | $21.80M 10-Q · filed 2017-05-04 | $45.86M derived: sum of 2 quarters · filed 2018-03-15 | $71.78M derived: sum of 3 quarters · filed 2018-03-15 | $98.79M derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2015-12-31 | $24.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $49.99M derived: sum of 2 quarters · filed 2018-03-15 | $76.99M derived: sum of 3 quarters · filed 2018-03-15 | $97.74M 10-K · filed 2018-03-15 | |||
| 2015-09-30 | $25.92M 10-Q · filed 2016-11-07 | $52.93M derived: sum of 2 quarters · filed 2016-11-07 | $73.68M 10-Q · filed 2016-11-07 | $93.72M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $27.01M 10-Q · filed 2016-08-04 | $47.76M 10-Q · filed 2016-08-04 | $67.80M derived: sum of 3 quarters · filed 2017-03-16 | $83.75M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $20.75M 10-Q · filed 2016-05-09 | $40.79M derived: sum of 2 quarters · filed 2017-03-16 | $56.74M derived: sum of 3 quarters · filed 2017-03-16 | $69.90M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $20.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $35.99M derived: sum of 2 quarters · filed 2017-03-16 | $49.15M derived: sum of 3 quarters · filed 2017-03-16 | $60.13M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $15.95M 10-Q · filed 2015-11-09 | $29.11M derived: sum of 2 quarters · filed 2015-11-09 | $40.09M 10-Q · filed 2015-11-09 | $49.78M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-06-30 | $13.16M 10-Q · filed 2015-08-10 | $24.14M 10-Q · filed 2015-08-10 | $33.83M derived: sum of 3 quarters · filed 2016-03-15 | $41.56M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-03-31 | $10.98M 10-Q · filed 2015-05-11 | $20.67M derived: sum of 2 quarters · filed 2016-03-15 | $28.41M derived: sum of 3 quarters · filed 2016-03-15 | $34.47M derived: sum of 4 quarters · filed 2016-03-15 | $63.81M 10-Q · filed 2014-05-08 | ||
| 2013-12-31 | $9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $17.43M derived: sum of 2 quarters · filed 2016-03-15 | $23.49M derived: sum of 3 quarters · filed 2016-03-15 | $28.45M 10-K · filed 2016-03-15 | $52.84M 10-K · filed 2014-03-21 | ||
| 2013-09-30 | $7.74M 10-Q · filed 2014-11-10 | $13.80M derived: sum of 2 quarters · filed 2014-11-10 | $18.76M 10-Q · filed 2014-11-10 | $22.43M derived: sum of 4 quarters · filed 2015-03-13 | $43.15M 10-Q/A · filed 2013-12-23 | ||
| 2013-06-30 | $6.06M 10-Q · filed 2014-08-07 | $11.03M 10-Q · filed 2014-08-07 | $14.69M derived: sum of 3 quarters · filed 2015-03-13 | $17.69M derived: sum of 4 quarters · filed 2015-03-13 | |||
| 2013-03-31 | $4.96M 10-Q · filed 2014-05-08 | $8.63M derived: sum of 2 quarters · filed 2015-03-13 | $11.63M derived: sum of 3 quarters · filed 2015-03-13 | ||||
| 2012-12-31 | $3.67M derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-03-13 | $6.66M derived: sum of 2 quarters · filed 2015-03-13 | $14.10M 10-K · filed 2015-03-13 | ||||
| 2012-09-30 | $3.00M 10-Q/A · filed 2013-12-23 | $10.43M 10-Q/A · filed 2013-12-23 | |||||
| 2011-12-31 | $8.62M 10-K · filed 2014-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |